Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers

In this episode,  Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:

• Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer
• Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancer
• Results from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancer

Presenters:

Nicole Concin, MD, PhD
Professor
Department of Gynaecology and Obstetrics
Medical University Innsbruck
Innsbruck, Austria
Consultant in Gynaecological Oncology
Department of Gynaecology and Gynaecologocial Oncology
KEM Evang. Kliniken Essen-Mitte
Essen, Germany

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/30PjPnl

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.